Six weeks after STAT reported that Eli Lilly granted a single 79-year-old patient special access to retatrutide, an unapproved obesity drug, the company confirmed on Monday that it will allow other patients to apply for early access. The announcement marks a striking change in the public posture of the pharmaceutical giant, which had previously offered little information about the special access program.
%20MH%20Testing/Larger%20Header%20Logos/STAT_Main2.png?height=88&upscale=true&name=STAT_Main2.png){kind=small}
%20MH%20Testing/Footer%20Icons/Flipboard-logo.png?width=60&height=60&upscale=true&name=Flipboard-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/X-logo.png?width=60&height=60&upscale=true&name=X-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Linkedin-logo.png?width=60&height=60&upscale=true&name=Linkedin-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Facebook-logo.png?width=60&height=60&upscale=true&name=Facebook-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Youtube-logo.png?width=60&height=60&upscale=true&name=Youtube-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Instagram-logo.png?width=60&height=60&upscale=true&name=Instagram-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Threads-logo.png?width=60&height=60&upscale=true&name=Threads-logo.png){kind=logo}